Trial Profile
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpower150
- Sponsors Chugai Pharmaceutical; Genentech; Roche
- 12 Sep 2023 Results of pooled analysis fromIMpower150, IMpower131, IMpower130; analyzing prognostic value of Lung Immune Prognostic Index (LIPI) in 1st-line CT +/- IT +/- antiangiogenics (AA), and its potential role in guiding treatment selection. presented at the 24th World Conference on Lung Cancer
- 19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research
- 19 Apr 2023 Results of digital and manual PD-L1 TC scores were compared and interrogated for their respective potential to predict efficacy to atezolizumab combination treatments, presented at the 114th Annual Meeting of the American Association for Cancer Research.